Skip to main content

Published locations for CTAD: New aducanumab subanalysis bolsters phase III trials in very mild Alzheimer’s

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. CTAD: New aducanumab subanalysis bolsters phase III trials in very mild Alzheimer’s

User login

  • Reset your password
  • /content/ctad-new-aducanumab-subanalysis-bolsters-phase-iii-trials-very-mild-alzheimers
  • /familypracticenews/article/104494/alzheimers-cognition/ctad-new-aducanumab-subanalysis-bolsters
  • /internalmedicinenews/article/104494/alzheimers-cognition/ctad-new-aducanumab-subanalysis-bolsters
  • /psychiatry/article/104494/alzheimers-cognition/ctad-new-aducanumab-subanalysis-bolsters-phase-iii
  • /internalmedicine/article/104494/alzheimers-cognition/ctad-new-aducanumab-subanalysis-bolsters-phase
  • /neurology/article/104494/alzheimers-cognition/ctad-new-aducanumab-subanalysis-bolsters-phase-iii
  • /familymedicine/article/104494/alzheimers-cognition/ctad-new-aducanumab-subanalysis-bolsters-phase
  • /clinicalneurologynews/article/104494/alzheimers-cognition/ctad-new-aducanumab-subanalysis-bolsters
  • /clinicalpsychiatrynews/article/104494/alzheimers-cognition/ctad-new-aducanumab-subanalysis-bolsters